NCT04231864 2020-10-26Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal CancerUniversity of California, San FranciscoPhase 2 Withdrawn